Work

724P Preliminary outcomes from a phase Ib/II study of the highly potent PI3K-mTOR dual inhibitor WX390 combined with toripalimab in patients with advanced cervical cancer

Year: 2024

Type: article

Study design: Clinical Trial

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2024.08.786

Authors: G. Li, A. Huang, Y. Zhao, B. Li, Y. Ding, S. Lai, J. Zhang, H. Zhu, D. Li, Q. Li, X. Jia, Y. Qi, Y. Li, Y. Guo

Institutions: Wuhan Union Hospital, Huazhong University of Science and Technology, Guilin Medical University, First Hospital of Jilin University, Yue Bei People's Hospital, First Affiliated Hospital of GuangXi Medical University, Xiangya Hospital Central South University, Shandong Tumor Hospital, Xiangyang Central Hospital, Tongji University, Shanghai East Hospital

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4402559939

FWCI: 0.177

Cites:

Cited by: 1

Related to: 10